Literature DB >> 2084074

Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.

H I Robins1, D S Neuberg, A B Benson, K J Pandya, D C Tormey.   

Abstract

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2084074     DOI： 10.1007/BF00198600

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  3 in total

1.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

2.  Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  P R Band; J Maroun; K Pritchard; D Stewart; C M Coppin; K Wilson; E A Eisenhauer
Journal:  Cancer Treat Rep       Date:  1986-11

3.  In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.

Authors:  G Zupi; C Greco; N Laudonio; M Benassi; B Silvestrini; A Caputo
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.